ES2185615T3 - Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa. - Google Patents

Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa.

Info

Publication number
ES2185615T3
ES2185615T3 ES91910707T ES91910707T ES2185615T3 ES 2185615 T3 ES2185615 T3 ES 2185615T3 ES 91910707 T ES91910707 T ES 91910707T ES 91910707 T ES91910707 T ES 91910707T ES 2185615 T3 ES2185615 T3 ES 2185615T3
Authority
ES
Spain
Prior art keywords
microcapsules
stimulate
growth
controlled release
nervous fiber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910707T
Other languages
English (en)
Inventor
Thomas R Tice
Deborah L Dillon
David W Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Research Institute
Original Assignee
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Research Institute filed Critical Southern Research Institute
Application granted granted Critical
Publication of ES2185615T3 publication Critical patent/ES2185615T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A MICROESFERAS POLIMERICAS COMO SISTEMAS INYECTABLES PARA LA LIBERACION DE MEDICAMENTOS PARA SU USO PARA LIBERAR AGENTES BIOACTIVOS EN LUGARES DENTRO DEL SISTEMA NERVIOSO CENTRAL, Y PARA LA ESTIMULACION DEL CRECIMIENTO DE LA FIBRA NERVIOSA MEDIANTE LA IMPLANTACION DE TALES MICROESFERAS DENTRO DEL SISTEMA NERVIOSO CENTRAL DE UN PACIENTE.
ES91910707T 1990-05-16 1991-05-14 Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa. Expired - Lifetime ES2185615T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52538390A 1990-05-16 1990-05-16

Publications (1)

Publication Number Publication Date
ES2185615T3 true ES2185615T3 (es) 2003-05-01

Family

ID=24093026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910707T Expired - Lifetime ES2185615T3 (es) 1990-05-16 1991-05-14 Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa.

Country Status (8)

Country Link
US (1) US5360610A (es)
EP (1) EP0528978B1 (es)
JP (2) JP3359919B2 (es)
AT (1) ATE226091T1 (es)
DE (1) DE69133136T2 (es)
DK (1) DK0528978T3 (es)
ES (1) ES2185615T3 (es)
WO (1) WO1991017772A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
AU8303691A (en) 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
EP1132080A3 (en) * 1992-09-10 2001-10-17 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5383873A (en) * 1992-12-09 1995-01-24 Regents Of The University Of Minnesota Smooth muscle chemical pacemaker
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
HUP9700322A3 (en) 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
US6303134B1 (en) 1996-08-29 2001-10-16 Advanced Research And Technology Institute, Inc. Pharmacotherapeutic process and composition for central nervous system disorders
CA2263898C (en) * 1996-09-16 2009-12-08 Purdue Research Foundation Composition and method for repairing neurological tissue
WO1999002139A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
AU3555599A (en) 1998-04-13 1999-11-01 Luminex Corporation Liquid labeling with fluorescent microparticles
IL143761A0 (en) * 1998-12-16 2002-04-21 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
CA2406846C (en) * 2000-04-21 2008-11-18 Advanced Research And Technology Institute, Inc. Pharmacotherapeutic process and composition for central nervous system disorders
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
EP1418890B1 (en) * 2001-08-16 2008-05-14 Baxter International Inc. Propellant-based microparticle formulations
US6488952B1 (en) * 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
EP1622691B1 (en) 2003-03-14 2011-05-25 The Trustees of Columbia University in the City of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
US20060076295A1 (en) 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
WO2005035088A2 (en) * 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005112885A2 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
EP1753404A1 (en) 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
CA2566079A1 (en) 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
WO2006047299A2 (en) * 2004-10-22 2006-05-04 University Of Florida Research Foundation, Inc. Organotypic slice cultures and uses thereof
WO2006097725A2 (en) * 2005-03-15 2006-09-21 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
AU2007253702A1 (en) 2006-05-22 2007-11-29 The Trustees Of Columbia University In The City Of New York Systems and methods of microfluidic membraneless exchange using filtration of extraction fluid outlet streams
WO2008006064A2 (en) * 2006-07-07 2008-01-10 Georgia Tech Research Corporation Biomimetic polymers and uses thereof
EP2647712A3 (en) 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CA2702340C (en) 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
CN100462105C (zh) * 2006-10-19 2009-02-18 中国人民解放军第四军医大学 一种重组合神经替代物的制备方法
CA2682135A1 (en) 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
WO2009100154A1 (en) 2008-02-04 2009-08-13 Trustees Of Columbia University In The City Of New York Fluid separation devices, systems and methods
DK2281042T3 (en) 2008-04-18 2015-11-09 Baxter Int Microsphere-based composition for preventing and / or deletion of starting autoimmune diabetes
ES2770273T3 (es) 2008-06-27 2020-07-01 Tepha Inc Administración inyectable de micropartículas y composiciones para ello
DK2326336T3 (en) 2008-07-30 2015-07-27 Mesynthes Ltd Tissue support structures from the extracellular matrix of a preform
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
EP2308478A1 (en) * 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
EP2635596B8 (en) 2010-11-01 2020-03-11 University of Technology Sydney Immune-modulating agents and uses therefor
EP3149049B1 (en) 2014-05-27 2022-10-26 The University Of Queensland Il-22 for use in treating metabolic disorders
KR102418503B1 (ko) * 2020-11-27 2022-07-07 주식회사 헤리노브 탄소섬유를 사용한 파이프 제조방법 및 이를 통해 제조된 파이프

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS6048923A (ja) * 1983-08-25 1985-03-16 Mitsui Toatsu Chem Inc 微小粒子の製造方法
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
JP2738881B2 (ja) * 1989-06-21 1998-04-08 ブラウン ユニバーシティ リサーチ ファウンデイション 神経治療システム
CH679207A5 (es) * 1989-07-28 1992-01-15 Debiopharm Sa
JP3187410B2 (ja) * 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤

Also Published As

Publication number Publication date
JP2003012506A (ja) 2003-01-15
JP3359919B2 (ja) 2002-12-24
EP0528978A4 (en) 1993-06-23
EP0528978A1 (en) 1993-03-03
US5360610A (en) 1994-11-01
WO1991017772A1 (en) 1991-11-28
JP4044366B2 (ja) 2008-02-06
DE69133136T2 (de) 2003-06-18
JPH05507486A (ja) 1993-10-28
ATE226091T1 (de) 2002-11-15
DE69133136D1 (de) 2002-11-21
DK0528978T3 (da) 2003-02-17
EP0528978B1 (en) 2002-10-16

Similar Documents

Publication Publication Date Title
DK0528978T3 (da) Mikrokapsler til reguleret afgivelse og deres anvendelse i stimulering af nervefibervækst
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
ES2167592T3 (es) Preparaciones medicamentosas que contienen un enantiomero de bromuro de ipratropio con duracion de la accion prolongada.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
DE69532673D1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
GT199800200A (es) Compuestos azapoliciclicos condensados con arilo.
ES2096312T3 (es) Derivado de quinuclidina como antagonista de la sustancia p.
ES2028074T3 (es) Activacion por humedad de un sistema de suministro transdermico de farmacos.
DE60036306D1 (de) System zur verabreichung von medikamenten mit veränderbarer rate
ES2043025T3 (es) Un procedimiento para preparar una composicion farmaceutica que contiene acido 3-(aminopropil)metil-fosfinico como agente terapeutico.
ES2087061T3 (es) Utilizacion de ribosido o ribotido de aica para la fabricacion de un medicamento contra la crisis cardiaca o el infarto de miocardio en los pacientes que sufren de ateroesclerosis.
MX9301634A (es) Quinuclidinas peptidicas.
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
ES2086623T3 (es) Azaheterociclilmetil-cromanos como principios activos para el tratamiento de enfermedades del sistema nervioso central.
ES2058592T3 (es) El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales.
MX9304110A (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento destinado a la profilaxis y a la terapia de enfermedades intestinales y cutaneas inflamatorias asi como de purpura.
ES2181742T3 (es) Derivados de benzoimidazol, su produccion y uso como antagonistas de angiotensina ii.
ES2145118T3 (es) Derivados de acidos grasos y composiciones farmaceuticas que los contienen.
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
ES2100632T3 (es) Una composicion de liberacion controlada que comprende un alginato reticulado con cationes multivalentes combinado con un acido poliacrilico.
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
ES2058426T3 (es) Empleo de antagonistas de serotonina en el tratamiento de apoplejia cerebral.
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen